Block­buster am­bi­tions: Am­gen/No­var­tis team lines up more promis­ing PhI­II erenum­ab da­ta for some of the tough­est mi­graine pa­tients

Am­gen $AMGN and its Big Phar­ma brethren at No­var­tis $NVS have lined up an­oth­er hap­py end­ing for the lat­est chap­ter on the mar­ket­ing pitch be­ing lined up for their pi­o­neer­ing CGRP mi­graine med.

Their drug Aimovig (erenum­ab) scored well in a study that re­cruit­ed some of the tough­est pa­tients in the world of mi­graine suf­fer­ers; men and women whose per­sis­tent mi­graines have re­sist­ed mul­ti­ple lines of ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER